Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2, and Libtayo, whose sales reached $285 million in Q1 2025.
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robust near-term revenue driver. Libtayo and the oncology pipeline offer potential, but face tough competition and are unlikely to become blockbuster catalysts in the short term. The company's move into obesity drugs is a favorable development, with considerable potential from its experimental drug Trevogrumab, which shows promise in early trial data.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion.
Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.
Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a mid-stage study.
Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal Consumption Expenditures data showed that inflation fell more than expected in April.
Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.